336 related articles for article (PubMed ID: 18089780)
1. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis.
Hinshelwood RA; Huschtscha LI; Melki J; Stirzaker C; Abdipranoto A; Vissel B; Ravasi T; Wells CA; Hume DA; Reddel RR; Clark SJ
Cancer Res; 2007 Dec; 67(24):11517-27. PubMed ID: 18089780
[TBL] [Abstract][Full Text] [Related]
2. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
3. Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta.
Ijichi H; Otsuka M; Tateishi K; Ikenoue T; Kawakami T; Kanai F; Arakawa Y; Seki N; Shimizu K; Miyazono K; Kawabe T; Omata M
Oncogene; 2004 Feb; 23(5):1043-51. PubMed ID: 14762439
[TBL] [Abstract][Full Text] [Related]
4. Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta.
Jazag A; Ijichi H; Kanai F; Imamura T; Guleng B; Ohta M; Imamura J; Tanaka Y; Tateishi K; Ikenoue T; Kawakami T; Arakawa Y; Miyagishi M; Taira K; Kawabe T; Omata M
Oncogene; 2005 Jan; 24(4):662-71. PubMed ID: 15592526
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
Osada H; Tatematsu Y; Masuda A; Saito T; Sugiyama M; Yanagisawa K; Takahashi T
Cancer Res; 2001 Nov; 61(22):8331-9. PubMed ID: 11719467
[TBL] [Abstract][Full Text] [Related]
6. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Lee BI; Park SH; Kim JW; Sausville EA; Kim HT; Nakanishi O; Trepel JB; Kim SJ
Cancer Res; 2001 Feb; 61(3):931-4. PubMed ID: 11221885
[TBL] [Abstract][Full Text] [Related]
7. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses.
Levy L; Hill CS
Mol Cell Biol; 2005 Sep; 25(18):8108-25. PubMed ID: 16135802
[TBL] [Abstract][Full Text] [Related]
8. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
9. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer.
Kang SH; Bang YJ; Im YH; Yang HK; Lee DA; Lee HY; Lee HS; Kim NK; Kim SJ
Oncogene; 1999 Dec; 18(51):7280-6. PubMed ID: 10602482
[TBL] [Abstract][Full Text] [Related]
11. The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold LI
Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
14. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF.
Bean GR; Bryson AD; Pilie PG; Goldenberg V; Baker JC; Ibarra C; Brander DM; Paisie C; Case NR; Gauthier M; Reynolds PA; Dietze E; Ostrander J; Scott V; Wilke LG; Yee L; Kimler BF; Fabian CJ; Zalles CM; Broadwater G; Tlsty TD; Seewaldt VL
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6834-41. PubMed ID: 18006786
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
Ai L; Kim WJ; Kim TY; Fields CR; Massoll NA; Robertson KD; Brown KD
Cancer Res; 2006 Aug; 66(16):7899-909. PubMed ID: 16912163
[TBL] [Abstract][Full Text] [Related]
16. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
17. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells.
Yamada N; Nishida Y; Tsutsumida H; Hamada T; Goto M; Higashi M; Nomoto M; Yonezawa S
Cancer Res; 2008 Apr; 68(8):2708-16. PubMed ID: 18413738
[TBL] [Abstract][Full Text] [Related]
18. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors.
Fraga MF; Herranz M; Espada J; Ballestar E; Paz MF; Ropero S; Erkek E; Bozdogan O; Peinado H; Niveleau A; Mao JH; Balmain A; Cano A; Esteller M
Cancer Res; 2004 Aug; 64(16):5527-34. PubMed ID: 15313885
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis.
Labbé E; Lock L; Letamendia A; Gorska AE; Gryfe R; Gallinger S; Moses HL; Attisano L
Cancer Res; 2007 Jan; 67(1):75-84. PubMed ID: 17210685
[TBL] [Abstract][Full Text] [Related]
20. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.
Leu YW; Yan PS; Fan M; Jin VX; Liu JC; Curran EM; Welshons WV; Wei SH; Davuluri RV; Plass C; Nephew KP; Huang TH
Cancer Res; 2004 Nov; 64(22):8184-92. PubMed ID: 15548683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
